Press Release

Newport Laboratories launches ParaSail

  • by
  • Mar 07, 2012

Newport Laboratories launches ParaSail® - industry's first avirulent live, single-dose vaccine for Haemophilus parasuis

WORTHINGTON, MN - Newport Laboratories is excited to announce the arrival of ParaSail, the swine industry's first avirulent live, single-dose vaccine for Haemophilus parasuis.

Available exclusively through veterinarians, ParaSail has been proven to protect against three of the most predominant strains of H. parasuis currently circulating: serotype 4 (found in 25% of cases), serotype 5 (found in 15% of all cases) and serotype 13. Multiple side-by-side comparisons have showed a single dose of the vaccine to be as effective as a two-dose regime. The USDA has approved ParaSail for use as a single-dose product with a 1mL dose size, intramuscular.

As Dr. Randy Simonson, COO of Newport Laboratories explained, ParaSail is backed by more than five years of research and development. One of the world's leading experts in H. parasuis, Dr. Simone Oliveira, originally led the R&D team in the early stages of the project, and she continued as a consultant in more recent years.

According to Simonson, scientific literature as well as practical experience has demonstrated that animals that have gone through an infection and survived, no matter the strain, appear to be immune to infection with heterologous strains. With this in mind, Oliveira and her team eventually discovered an attenuated strain that was safe in pigs and provided broad-spectrum immunity; that strain was the foundation for ParaSail.

ParaSail has been proven to be safe for use in pigs 21 days of age or older. In numerous challenge studies, pigs vaccinated with ParaSail showed decreased incidence of fevers and disease lesions, and minimal mortality compared with placebo-vaccinated control animals.

ParaSail's patent-pending formulation enables it to replicate a non-disease-causing copy of H. parasuis in vaccinated animals, thus stimulating and immune response that is second only to the actual infection.

Newport Laboratories has been producing PINPOINT™ Evidence-based H. parasuis biologicals for a number of years, Simonson said. "However, as with the killed commercial products, these biologics tend to work when the strains in the vaccine are similar to those in the field. With ParaSail, we have demonstrated cross-protection against heterologous challenge as well."

H. parasuis continues to become more and more prevalent in U.S. swine herds. In a recent survey of state veterinary diagnostic laboratories conducted by Newport Laboratories, the incidence of H. parasuis among all cases submitted ranged up to as high as 40 percent. The most recent report from the USDA National Animal Health Monitoring System (NAHMS) revealed that the incidence of H. parasuis is on the rise, with a 230% increase in nursery pig incidence and a 340% increase in grower/finisher pig incidence from 2000 to 2006.

ParaSail is the first commercially license commercial vaccine to be produced by Newport Laboratories; however Simonson said it is only the beginning for the company, which is recognized as the nation's leading producer of PINPOINT Evidence-based Biologics.

"ParaSail is our leading entry into what we believe will become a unique and novel platform of new vaccines," he said.

ParaSail is available exclusively through veterinarians.